Dexcom COO Quentin Blackford Takes CEO Job At iRhythm
Executive Summary
The move is supported by iRhythm investors and disappointed Dexcom’s shareholders.
You may also be interested in...
Exec Chat: New iRhythm CEO Foresees Enormous Opportunity In AI For Arrhythmia Detection
Quentin Blackford, who recently became iRhythm’s CEO after serving as Dexcom’s chief operating officer, talked to Medtech Insight about the challenges and opportunities in the emerging remote cardiac monitoring market.
MTI 100 2022: Big Cardio Medtechs Are Moving ESG Agenda To Center Stage
Medtech Insight outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.
Big Cardio Medtechs Are Moving ESG Agenda To Center Stage In 2022
In Vivo outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.